You can buy or sell KALV and other stocks, options, ETFs, and crypto commission-free!
KalVista Pharmaceuticals, Inc. Common Stock, also called KalVista Pharmaceuticals, is a pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Read More It offers small molecule plasma kallikrein for the treatment of hereditary angioedema; diabetic macular edema; and other plasma kallikrein-associated diseases. The company was founded by Crockett, T. Andrew, Edward P. Feener, and Lloyd P. Aiello and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
KalVista Pharmaceuticals Presents Data at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2019
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced data from a poster presentation given Saturday, February 23, at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2019 in San Francisco, CA. “We are pleased to provide additional data on KVD900, showcasing a potentially ideal profile...
-$0.45 per share
-$0.23 per share